890839-29-9

Usage

Uses

Used in Pharmaceutical Research and Development:
Tert-butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole-1-carboxylate is used as a key intermediate in the synthesis of pharmaceutical agents for various therapeutic applications. Its unique structure and reactivity enable the development of novel drug candidates with improved efficacy and selectivity.
Used in Agrochemicals:
In the agrochemical industry, tert-butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole-1-carboxylate is used as a building block for the synthesis of agrochemicals, such as pesticides and herbicides. Its versatile reactivity allows for the creation of new compounds with enhanced performance and selectivity in controlling pests and weeds.
Used in Fine Chemicals:
Tert-butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole-1-carboxylate is also utilized in the preparation of other fine chemicals, such as specialty chemicals and intermediates for various industrial applications. Its unique properties make it a valuable component in the synthesis of high-value products.

Upstream product

• 937049-58-6 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole 
• 24424-99-5 di-tert-butyl dicarbonate 
• 877264-77-2 1,1-dimethylethyl 6-bromo-1H-indazole-1-carboxylate 
• 73183-34-3 bis(pinacol)diborane 
• 79762-54-2 6-bromo-1H-indazole 

Relevant academic research and scientific papers

COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY

The present invention is directed to substituted certain reversed indazole compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R9, and A are as defined herein, which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

FATTY ACID SYNTHASE INHIBITORS

This invention relates to carboxamides and reverse carboxamides according to Formula (I) and the use of carboxamides and reverse carboxamides for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of carboxamides and reverse carboxamides in the treatment of cancer.

FATTY ACID SYNTHASE INHIBITORS

This invention relates to the use of imidazole, triazole, and tetrazole derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of imidazoles, triazoles, and tetrazoles in the treatment of cancer.

1H-PYRROLO[2,3-B]PYRIDINES

Derivatives of pyrrolo[2,3-b]pyridine which are useful as SGK-1 kinase inhibitors are described herein. The invention described herein also describes pharmaceutical compositions containing derivatives of pyrrolo[2,3-b]pyridine and methods of using pyrrolo[2,3-b]pyridine derivatives and pharmaceutical compositions thereof in the treatment of diseases mediated by SGK-1.